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BACKGROUND: Evidence from randomized trials has shown that 
therapies that lower LDL (low-density lipoprotein)-cholesterol and 
triglycerides reduce coronary artery disease (CAD) risk. However, there 
is still uncertainty about their effects on other cardiovascular outcomes. 
We therefore performed a systematic investigation of causal relationships 
between circulating lipids and cardiovascular outcomes using a Mendelian 
randomization approach.
METHODS: In the primary analysis, we performed 2-sample multivariable 
Mendelian randomization using data from participants of European 
ancestry. We also conducted univariable analyses using inverse-variance 
weighted and robust methods, and gene-specific analyses using variants 
that can be considered as proxies for specific lipid-lowering medications. 
We obtained associations with lipid fractions from the Global Lipids 
Genetics Consortium, a meta-analysis of 188 577 participants, and 
genetic associations with cardiovascular outcomes from 367 703 
participants in UK Biobank.
RESULTS: For LDL-cholesterol, in addition to the expected positive 
associations with CAD risk (odds ratio [OR] per 1 SD increase, 1.45 
[95% CI, 1.35–1.57]) and other atheromatous outcomes (ischemic 
cerebrovascular disease and peripheral vascular disease), we found 
independent associations of genetically predicted LDL-cholesterol with 
abdominal aortic aneurysm (OR, 1.75 [95% CI, 1.40–2.17]) and aortic 
valve stenosis (OR, 1.46 [95% CI, 1.25–1.70]). Genetically predicted 
triglyceride levels were positively associated with CAD (OR, 1.25 [95% 
CI, 1.12–1.40]), aortic valve stenosis (OR, 1.29 [95% CI, 1.04–1.61]), and 
hypertension (OR, 1.17 [95% CI, 1.07–1.27]), but inversely associated 
with venous thromboembolism (OR, 0.79 [95% CI, 0.67–0.93]) and 
hemorrhagic stroke (OR, 0.78 [95% CI, 0.62–0.98]). We also found 
positive associations of genetically predicted LDL-cholesterol and 
triglycerides with heart failure that appeared to be mediated by CAD.
CONCLUSIONS: Lowering LDL-cholesterol is likely to prevent 
abdominal aortic aneurysm and aortic stenosis, in addition to CAD and 
other atheromatous cardiovascular outcomes. Lowering triglycerides 
is likely to prevent CAD and aortic valve stenosis but may increase 
thromboembolic risk.
ORIGINAL ARTICLE
Genetic Determinants of Lipids and 
Cardiovascular Disease Outcomes
A Wide-Angled Mendelian Randomization Investigation
© 2019 The Authors. Circulation: 
Genomic and Precision Medicine is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
Elias Allara, MD
Gabriele Morani, PhD
Paul Carter, MB BS
Apostolos Gkatzionis, PhD
Verena Zuber, PhD
Christopher N. Foley, PhD
Jessica M.B. Rees, PhD




Adam S. Butterworth, 
PhD
Emanuele Di  
Angelantonio, MD, PhD
James Peters, MB ChB, PhD
Stephen Burgess, PhD
INVENT consortium*
*Please refer to the Data Supplement 
for complete author list.
Key Words: aortic valve stenosis 
◼ epidemiology ◼ lipids ◼ 
Mendelian randomization ◼ venous 
thromboembolism




Allara et al; Genetics of Lipids and Cardiovascular Diseases
Circ Genom Precis Med. 2019;12:e002711. DOI: 10.1161/CIRCGEN.119.002711 December 2019 544
Evidence from randomized trials has shown that therapies that lower low-density lipoprotein (LDL)-cholesterol, such as statins, are beneficial for pre-
venting or treating several atheromatous diseases such 
as coronary artery disease (CAD),1 ischemic stroke,2 and 
peripheral vascular disease,3,4 as well as both postoper-
ative atrial fibrillation5 and heart failure in the presence 
of underlying CAD.6,7 However, for other cardiovascular 
outcomes, such as thromboembolic disease,8 hemor-
rhagic stroke,9,10 and aortic aneurysms,11,12 the effects 
of LDL-cholesterol lowering are less clear. Recently, the 
REDUCE-IT trial has shown that therapies that predomi-
nantly lower triglycerides can reduce major cardiovas-
cular events.13 However, the effects of triglyceride low-
ering on nonatheromatous cardiovascular outcomes 
are largely unknown.
Although a randomized trial is the gold standard of 
evidence and is required to conclusively establish the 
effectiveness of a treatment, naturally occurring genetic 
variants can be used to help predict the outcome of a 
randomized trial in an approach known as Mendelian 
randomization (MR).14 For example, this approach has 
been used successfully to attest the effects of statins and 
predict the effects of PCSK9 (proprotein convertase sub-
tilisin/kexin type 9) inhibitors on CAD risk seen in random-
ized trials.15,16 MR investigations have also shown positive 
associations of genetically predicted LDL-cholesterol with 
abdominal aortic aneurysm,17 ischemic stroke,18 and aor-
tic stenosis,19 and positive associations of triglycerides 
with CAD.20 While MR makes strong assumptions includ-
ing the genetic variants used in the analysis only influ-
ence the outcome via the stated risk factors,21 when both 
approaches can be undertaken MR has generally given 
results that agree with randomized trials.22
However, MR approaches have not yet been used 
to investigate the relationship between circulating lip-
ids and some major cardiovascular conditions such as 
venous thromboembolism and heart failure. Addition-
ally, approaches to estimate the independent effects of 
LDL-cholesterol, triglycerides, and high-density lipopro-
tein (HDL)-cholesterol on cardiovascular disease while 
accounting for genetic pleiotropy have only been per-
formed for a limited set of outcomes.17,19,20
Our objective in this paper is to assess which cardio-
vascular outcomes could be treated by lipid-lowering 
therapies. We performed a systematic MR analysis of 
atheromatous and nonatheromatous cardiovascular 
disease outcomes. We considered disease outcomes 
in a single dataset (UK Biobank) to ensure a consistent 
approach to the analysis across different outcomes. We 
carried out polygenic analyses for each of LDL-choles-
terol, HDL-cholesterol, and triglycerides, based on all 
common genetic variants associated with at least one 
of these risk factors, as well as gene-specific analyses 




Summary statistics for the genetic associations with lipid frac-
tions were taken from the Global Lipids Genetics Consortium, 
and are available at http://csg.sph.umich.edu/willer/public/
lipids2013.23,24 Summary statistics for the genetic associa-
tions with outcomes were estimated in UK Biobank, and for 
replication with venous thromboembolism in the INVENT 
(International Network Against Venous Thrombosis) consor-
tium (restricting to European descent participants and exclud-
ing participants from UK Biobank). Because of the sensitive 
nature of some of the data collected for this study, requests 
to access the datasets from qualified researchers trained in 
human subject confidentiality protocols may be sent to UK 
Biobank at https://www.ukbiobank.ac.uk/register-apply,25 and 
to the INVENT consortium by contacting the senior authors 
and Co-Conveners of the Consortium, Drs David-Alexandre 
Tregouet and Nicholas L. Smith.26
UK Biobank and all studies in these consortia were 
approved by their respective institutional review committee 
and their participants gave informed consent.
The methods are available in the Data Supplement.
RESULTS
Participant Characteristics
Baseline characteristics of the participants in the UK 
Biobank are provided in Table 1. Around 46% of par-
ticipants were men, and the mean age was 57 years. 
Around 10% were smokers, 93% were alcohol drink-
ers, and 4% had a history of diabetes mellitus at 
baseline.
Polygenic Analyses for All Lipid-Related 
Variants
Multivariable MR estimates are displayed graphically in 
Figure 1 and summarized in Table I in the Data Supple-
ment. Estimates of heterogeneity between the causal 
estimates from different variants are provided in Tables 
II and III in the Data Supplement, and scatter plots of 
genetic associations for selected risk factor/outcome 
pairs are provided in Figure I in the Data Supplement. 
Significant heterogeneity was observed for several out-
comes, although this is unsurprising given the number 
of genetic variants included in the analyses. Associa-
tions with the positive control outcome (CAD) were as 
expected for LDL-cholesterol and triglycerides. There 
were no associations with the negative control out-
come (chronic kidney disease).
We found a strong association of genetically predict-
ed LDL-cholesterol with CAD risk (odds ratio [OR] per 
1 SD increase, 1.45 [95% CI, 1.35–1.57]), which was 
within the reference range of a previous study.20 The 
strongest associations by magnitude were for abdomi-
nal aortic aneurysm (OR, 1.75 [95% CI, 1.40–2.17), 
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aortic valve stenosis (OR, 1.46 [95% CI, 1.25–1.70]), 
aortic aneurysm (OR, 1.43 [95% CI, 1.21–1.68]), and 
heart failure (OR, 1.17 [95% CI, 1.06–1.28]), which all 
met our threshold for statistical significance (P<0.003). 
We also observed a significant positive association for 
the combined outcome of ischemic stroke and tran-
sient ischemic attack (OR, 1.14 [95% CI, 1.04–1.24]). 
We saw positive associations at a nominal significance 
level (0.003 ≤ P < 0.05) for LDL-cholesterol with risk of 
transient ischemic attack and risk of peripheral vascu-
lar disease. The association with ischemic stroke was 
in the positive direction but nonsignificant (OR, 1.10 
[95% CI, 0.98–1.23]).
Genetically predicted triglyceride levels were 
strongly associated with increased risk of coro-
nary heart disease (CAD), consistent with previous 
results,20 as well as with increased risk of hyperten-
sion (OR, 1.17 [95% CI, 1.07–1.27]). Positive nominal 
associations were noted also for aortic valve stenosis 
and heart failure. A nominally significant inverse asso-
ciation was observed with hemorrhagic stroke, in par-
ticular with intracerebral hemorrhage (OR, 0.65 [95% 
CI, 0.49–0.86]). Inverse nominal associations were 
observed for triglycerides with all of the thromboem-
bolic diseases we analyzed: deep vein thrombosis (OR, 
0.78 [95% CI, 0.65–0.93]), pulmonary embolism (OR, 
0.78 [95% CI, 0.64–0.96]), and any venous thrombo-
embolism (OR, 0.79 [95% CI, 0.67–0.93]). A similar 
association with venous thromboembolism was esti-
mated in a separate sample of 129 002 individuals of 
European ancestry from the INVENT consortium (OR, 
0.84 [95% CI, 0.70–1.01]; P=0.057; Table 2). Geneti-
cally predicted HDL-cholesterol was nominally associ-
ated with lower risk of coronary heart disease (OR, 
0.91 [95% CI, 0.83–1.00]) and hypertension and more 
strongly inversely associated with abdominal aortic 
aneurysm (OR, 0.65 [95% CI, 0.51–0.85]) and intra-
cerebral hemorrhage (OR, 0.65 [95% CI, 0.51–0.82]). 
In exploratory analyses to investigate these findings, 
genetically predicted triglyceride levels were positively 
associated with tissue-type plasminogen activator but 
not with platelet count (Table IV in the Data Supple-
ment). Positive associations were observed between 
genetically predicted triglycerides and both systolic 
and diastolic blood pressure, whereas inverse associa-
tions with HDL-cholesterol were not replicated (Table 
V in the Data Supplement).
Univariable MR estimates for each lipid risk factor in 
turn are displayed in Figures II through IV in the Data 
Supplement and summarized in Tables VI through VIII 
in the Data Supplement. Similar results were generally 
obtained from each of the univariable methods as for 
the multivariable methods, although CIs were slightly 
wider in some cases, especially for the MR-Egger meth-
od. The association between HDL-cholesterol and CAD 
became null in MR-Egger regression (OR, 0.99 [95% CI, 
0.83–1.19]). Similarly, the associations of triglycerides 
with hemorrhagic stroke and its subtypes attenuated to 
the null in almost all univariable analyses (Table VIII in 
the Data Supplement). Another notable difference was 
a positive association of genetically predicted triglycer-
ides with increased aortic aneurysm risk, particularly for 
abdominal aortic aneurysm. While the association with 
aortic aneurysm was not strongly apparent in the multi-
variable analysis, it was evident for each of the univari-
able analysis methods.
We also assessed whether the associations of 
genetically predicted lipids with outcomes that are 
comorbid with CAD (eg, heart failure) may be mediat-
ed via CAD, and similarly for outcomes that are comor-
bid with type 2 diabetes mellitus (T2D), for example, 
hypertension. On adjustment for CAD risk (Table  3), 
Table 1. Baseline Characteristics of UK Biobank Participants Included 
in This Study and Numbers of Outcome Events
Characteristic Mean (SD) or N (%)
Sample size 367 703 (100)
Male 168 799 (45.9)
Age at baseline 57.2 (8.1)
Body mass index 27.3 (4.8)
Systolic blood pressure 137.6 (18.6)
Diastolic blood pressure 82.0 (10.1)
Smoking status (current/ex/never)* 37 866 (10.3)/185 704 
(50.5)/143 777 (39.1)
Alcohol status (current/ex/never)* 342 797 (93.2)/12 732 
(3.5)/11 646 (3.2)
History of type 2 diabetes mellitus 15 834 (4.3)
Coronary artery disease 29 278 (8.0)
Ischemic cerebrovascular event (all) 8084 (2.2)
  Ischemic stroke 4602 (1.3)
  Transient ischemic attack 3962 (1.1)
Hemorrhagic stroke (all) 1981 (0.5)
  Intracerebral hemorrhage 1064 (0.3)
  Subarachnoid hemorrhage 1084 (0.3)
Aortic aneurysm (all) 1849 (0.5)
  Abdominal aortic aneurysm 1094 (0.3)
  Thoracic aortic aneurysm 347 (0.1)
Venous thromboembolism (all) 14 097 (3.8)
  Deep vein thrombosis 9454 (2.6)
  Pulmonary embolism 6148 (1.7)
Hypertension 125 846 (34.2)
Peripheral vascular disease 3415 (0.9)
Aortic valve stenosis 2244 (0.6)
Atrial fibrillation 16 945 (4.6)
Heart failure 6712 (1.8)
Chronic kidney disease 6321 (1.7)
*Excluding 356 participants with smoking status absent and 528 
participants with alcohol consumption status absent.
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the associations of genetically predicted LDL-choles-
terol and triglycerides with heart failure attenuated 
sharply, suggesting that their effects on heart failure 
might be mediated via CAD. As a negative control, we 
also performed the same analysis for abdominal aortic 
aneurysm. The association with genetically predicted 
LDL-cholesterol attenuated slightly but was still clearly 
positive. We also performed multivariable MR analyses 
excluding participants with CAD for heart failure (2383 
remaining cases). This analysis gave null estimates for 
all lipid fractions (Table IX in the Data Supplement). 
This suggests that LDL-cholesterol is unlikely to be a 
causal risk factor for heart failure where there is no 
comorbidity with CAD. On adjustment for body mass 
index and T2D mellitus (Table X in the Data Supple-
ment), associations between lipids and hypertension, 
abdominal aortic aneurysm, and hemorrhagic stroke 
did not change substantially compared with unadjust-
ed analyses, suggesting that neither body mass index 
nor T2D mellitus is likely to mediate the effects of lip-
ids on these outcomes. While adjusting for heart fail-
ure, heart failure was strongly associated with venous 
thromboembolism, but associations between lipids 
and venous thromboembolism did not change mark-
edly (Table X in the Data Supplement). This confirms 
that heart failure is an independent risk factor for 
venous thromboembolism but suggests it is unlikely 
to mediate the association between triglycerides and 
venous thromboembolism.
Gene-Specific Analyses for Drug Proxy 
Variants
MR estimates for specific gene regions are displayed 
graphically in Figure 2 and summarized in Tables XI and 
XII in the Data Supplement . All the gene regions ana-
lyzed showed clear associations with CAD risk, confirm-
ing their involvement in cardiovascular disease etiology 
and the relevance of existing and proposed lipid-lower-
ing therapies for CAD risk reduction.
Results for the low-density lipoprotein recep-
tor (LDLR) gene regions, and to a lesser extent for 
3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) 
and PCSK9, were similar to those for LDL-cholesterol 
Figure 1. Multivariable Mendelian randomization estimates (odds ratio with 95% confidence interval per 1 standard deviation increase in lipid frac-
tion) from polygenic analyses including all lipid-associated variants.  
HDL indicates high-density lipoprotein; and LDL, low-density lipoprotein.
Table 2. Replication and Meta-Analysis of the Association Between Genetically Predicted Triglycerides and Risk of Venous 
Thromboembolism in the INVENT Consortium (Odds Ratios with 95% Confidence Intervals)
Venous Thromboembolism N Events/Participants HDL-Cholesterol LDL-Cholesterol Triglycerides
UK Biobank 14 097 / 367 703 0.94 (0.82–1.08) 1.03 (0.92–1.16) 0.79 (0.67–0.93)*
INVENT 15 572 / 129 002 1.03 (0.89–1.20) 1.07 (0.94–1.21) 0.84 (0.70–1.01)
UK Biobank+INVENT 29 669 / 496 705 0.98 (0.86–1.12) 1.05 (0.94–1.17) 0.81 (0.69–0.95)*
All estimates are odds ratios estimated using multivariable inverse-variance weighted Mendelian randomization accounting for lipid-related 
genetic pleiotropy and between-variant heterogeneity (random-effects analyses). HDL indicates high-density lipoprotein; and LDL, low-density 
lipoprotein.
*P<0.05
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in the polygenic analyses, although with wider con-
fidence intervals. Significant positive associations 
were obtained for LDLR with aortic and abdominal 
aortic aneurysm, venous thromboembolism, aortic 
valve stenosis, and heart failure, and an inverse asso-
ciation was observed for subarachnoid hemorrhage. 
Variants in the HMGCR gene region were inversely 
associated with intracerebral hemorrhage (P=0.022). 
Results for apolipoprotein C3 (APOC3) and lipopro-
tein lipase (LPL) followed a pattern more similar to the 
analysis for triglycerides, showing inverse associations 
with thromboembolic diseases (P=0.007 for APOC3, 
P=0.089 for LPL for any venous thromboembolism). 
In both regions, associations with aortic aneurysm, 
aortic valve stenosis and hypertension were all posi-
tive. Additionally, variants in the LPL region were also 
positively associated with all ischemic cerebrovascular 
diseases.
DISCUSSION
In this study, we assessed the causal role of 3 major 
lipid fractions for a range of cardiovascular diseases in 
a large population-based cohort using the principle of 
MR while accounting for genetic pleiotropy between 
the lipid measures. Our most notable findings were the 
associations between genetically predicted triglycerides 
and decreased risk of thromboembolic diseases both in 
polygenic analyses and in gene-specific analyses for the 
APOC3 gene region, suggesting that reducing triglyc-
erides may increase risk for venous thromboembolism. 
Additionally, as summarized in Table XIII in the Data 
Supplement, we found: (1) evidence supporting the 
current understanding of the cause of CAD, suggest-
ing independent causal roles for LDL-cholesterol and 
triglycerides, both in the polygenic analyses and for all 
the drug-related gene-specific analyses20,27; (2) positive 
associations of genetically predicted LDL-cholesterol 
with abdominal aortic aneurysm and aortic valve ste-
nosis, as well as atheromatous cardiovascular outcomes 
that are already addressed in clinical guidelines (eg, 
peripheral vascular disease and the combined outcome 
of ischemic stroke and transient ischemic attack); (3) 
positive associations of genetically predicted LDL-cho-
lesterol and triglycerides with heart failure that appear 
to be mediated by CAD; (4) associations between 
genetically predicted triglycerides and increased risk of 
aortic stenosis and hypertension; and (5) inverse asso-
ciations between genetically predicted HDL-cholester-
ol and abdominal aortic aneurysm and hemorrhagic 
stroke (in particular, intracerebral hemorrhage) that 
seem to be independent of body mass index/type 2 dia-
betes mellitus.
The importance of these findings is 3-fold. First, 
they help us to better understand the etiology and 
pathophysiology of common cardiovascular outcomes, 
and so to identify additional potential indications for 
lipid-lowering therapies. Second, association estimates 
provided in this paper can inform calculations on the 
risk-benefit and cost-benefit of these therapies. Third, 
these findings can aid identification of which patients 
would most benefit from (or should avoid) lipid-lower-
ing therapies.
Table 3. Multivariable Mendelian Randomization Estimates (Odds Ratio With 95% CI) for Heart Failure Without and With 
Adjustment for CAD Risk
HDL-Cholesterol LDL-Cholesterol Triglycerides CAD
Heart failure
  Without adjustment for CAD risk 0.97 1.17 1.19 -
(0.87–1.08) (1.06–1.28)* (1.04–1.37)†  
  With adjustment for CAD risk 1.02 0.95 1.06 1.73
(0.92–1.13) (0.85–1.06) (0.93–1.20) (1.47–2.04)‡
Abdominal aortic aneurysm
  Without adjustment for CAD risk 0.65 1.75 0.94 -
(0.51–0.85)* (1.40–2.17)* (0.68–1.28)  
  With adjustment for CAD risk 0.69 1.46 0.84 1.60
(0.53–0.88)* (1.12–1.91)* (0.61–1.16) (1.06–2.42)†
Analyses were also performed for abdominal aortic aneurysm as a negative control. The CAD column indicates the association between 
genetically predicted coronary artery disease and the outcome of interest (ie, heart failure or abdominal aortic aneurysm) while accounting 
for the genetic associations of the lipid fractions in a multivariable analysis. If the regression coefficients for the lipid measurements remain 
unchanged on adjustment for CAD, then the effects of lipids on the outcome do not operate via CAD. If the regression coefficients attenuate 
to the null, then the effects of lipids on the outcome are entirely mediated via CAD. CAD indicates Coronary Artery Disease; HDL, high-density 
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Genetic predisposition to lower triglycerides was 
associated with an increased risk of thromboembolic 
diseases. In contrast, previous observational evidence 
did not suggest an association between triglycerides 
and venous thrombosis,28,29 although other lipid mea-
sures (in particular apolipoprotein B and lipoprotein[a]) 
were inversely associated with venous thrombosis mor-
tality in a meta-analysis of over 700 000 participants 
from the Emerging Risk Factors Collaboration.29 Our 
result was consistent across 3 of the 4 MR methods and 
was replicated using data from the INVENT consortium, 
an independent data source for genetic associations 
with the outcome. Associations with thromboembolic 
outcomes using the MR-Egger method were slightly 
attenuated and compatible with the null, raising the 
possibility of unmeasured genetic pleiotropy, although 
this method generally has lower power compared with 
the conventional inverse-variance weighted method.30 
Variants in the APOC3 gene region were associated 
with thromboembolic events, suggesting that lower-
ing triglyceride levels via intervening on this pathway 
may increase thromboembolism risk. Additionally, the 
positive genetic association between triglycerides and 
tissue-type plasminogen activator reported here con-
firms the findings of a previous observational study 
among 1227 men free of coronary heart disease.31 
However, genetically predicted triglycerides were not 
associated with platelet count. This is in contrast to 
the APPROACH trial, a trial of triglyceride-lowering 
therapy in patients with familial chylomicronemia, in 
which thrombocytopenia led to excess early termina-
tions among patients with familial chylomicronemia32 
but in line with (1) 2 other trials of APOC3 inhibi-
tors33,34 and (2) with the fluctuations in platelet counts 
(both thrombocytopenia and thrombocytosis) noted in 
an observational study of 86 patients with familial chy-
lomicronemia.35 Further investigation is needed to con-
firm the unexpected genetic association of triglycerides 
with venous thromboembolism.
Both the positive association between genetic predic-
tors of LDL-cholesterol and abdominal aortic aneurysm, 
and the inverse association for HDL-cholesterol, repli-
cate a previous MR study which did not include UK Bio-
bank participants.17 This evidence is complemented by a 
randomized trial that has shown benefit from screening 
and treating abdominal aortic aneurysm using various 
interventions including statins.11 No significant asso-
ciation was seen with thoracic aortic aneurysm, in line 
with the different pathophysiology of the 2 disease sub-
types.36 Overall, these findings provide further support 
to the hypothesis that increased LDL-cholesterol has 
deleterious effects on abdominal aortic aneurysm and 
suggest that LDL-cholesterol lowering therapies may be 
beneficial in preventing abdominal aortic aneurysm.
Similarly, the positive association between geneti-
cally predicted LDL-cholesterol and aortic valve stenosis 
replicates a previous MR study.19 We also demonstrated 
a positive association for triglycerides, in line with the 
previous study (although their result did not achieve 
conventional levels of statistical significance). Our asso-
ciation was robust to all sensitivity analyses and evi-
denced in gene-specific analyses for both the APOC3 
and LPL loci. These findings are consistent with previ-
ous observational and pathological studies suggesting a 
role of atherosclerotic processes in early valve lesions37,38 
whereas clinical trials showed no benefit from LDL-
cholesterol lowering via statins on aortic stenosis pro-
gression.39 Taken together, this suggests that increased 
LDL-cholesterol and triglycerides may facilitate initiation 
of early lesions, but that lipid-lowering therapies may 
be ineffective in preventing the progression of aortic 
stenosis.
Figure 2. Univariable Mendelian randomization estimates (odds ratio with 95% CI per 1 SD increase in lipid fraction) for variants in specific 
gene regions.  
Estimates are scaled to a unit SD increase in LDL-cholesterol for the HMGCR, PCSK9, and LDLR regions, and to a SD increase in triglycerides for the APOC3 and LPL regions.
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CAD is a well-known risk factor for heart failure,40 as 
myocardial ischemic damage reduces myocardial con-
tractility and ventricular function. Associations of heart 
failure with genetically predicted LDL-cholesterol and 
triglycerides disappeared after adjusting for CAD. The 
association was also absent when omitting participants 
with a CAD diagnosis from analyses. In contrast, associ-
ations with abdominal aortic aneurysm attenuated only 
slightly after adjustment for CAD. Overall, these results 
suggest that lipid-lowering therapies are only likely to 
influence risk of heart failure via their effects on CAD.
Our analyses also identified inverse associations of 
genetically predicted HDL-C and triglyceride levels with 
risk of intracerebral hemorrhage (albeit the latter asso-
ciation was not robust to most sensitivity analyses), 
consistent with a recent observational analysis for tri-
glycerides.41 Furthermore, we identified a detrimental 
effect of HMGCR inhibition on intracerebral hemor-
rhage risk, in keeping with a large randomized trial of 
atorvastatin in patients with recent transient ischemic 
attack or stroke, which found statin therapy to lower 
risk of major cardiovascular events but increase the risk 
of hemorrhagic stroke.42 However, this finding has not 
been replicated in large meta-analyses.43 The mecha-
nism relating lipid traits with risk of intracerebral hem-
orrhage requires further exploration.
Finally, the inverse association between HDL-cho-
lesterol and CAD was only nominally significant in the 
main multivariable analyses but became null with MR-
Egger regression, suggesting that HDL-cholesterol is 
unlikely to be a causal risk factor for CAD.
Our investigation has both strengths and limitations. 
The large sample size of over 360 000 participants and 
the broad set of outcomes analyzed render this one of 
the most comprehensive MR analyses on cardiovascular 
disease conducted to date. Availability of multiple cardio-
vascular conditions within the same study enabled cross-
comparisons between diseases and enabled us to perform 
adjusted analyses in the same participants and to assess 
mediation of causal effects. This investigation has a num-
ber of limitations. Lack of publicly available summary data 
from external datasets prevented us from performing rep-
lication analyses for some associations, for example, those 
for heart failure. This design still allows sensitivity analy-
ses such as MR-Egger and the weighted median estima-
tor which enabled us to investigate and account for the 
possible presence of genetic pleiotropy and gene-specific 
analyses that are less likely to be influenced by pleiotropy 
as they only include variants from a single gene region 
where the function is well known. Significant heteroge-
neity was observed in the polygenic analysis for several 
outcomes, suggesting that some variants may have pleio-
tropic effects. Additionally, this investigation was con-
ducted in UK-based middle- to late-aged participants of 
European ancestries. While this is recommended for MR 
to ensure that genetic associations are not influenced by 
population stratification, it means that results may not be 
generalizable to other ethnicities or nationalities.
In conclusion, multivariable MR analyses accounting 
for lipid-related genetic pleiotropy support the hypoth-
esis that circulating lipids have causal effects on a wide 
range of cardiovascular diseases. Interventions that 
lower LDL-cholesterol are likely to be beneficial in pre-
venting aortic aneurysm and aortic stenosis in addition 
to several other atheromatous diseases. Triglyceride-
lowering treatments are likely to be beneficial in pre-
venting CAD and aortic valve stenosis, but caution is 
needed due to the possibility of increased risk of venous 
thromboembolism.
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